Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116


Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: an analysis from ACT34-CMI.

Povsic TJ, Losordo DW, Story K, Junge CE, Schatz RA, Harrington RA, Henry TD.

Am Heart J. 2012 Nov;164(5):689-697.e3. doi: 10.1016/j.ahj.2012.06.022.


A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study.

Povsic TJ, Junge C, Nada A, Schatz RA, Harrington RA, Davidson CJ, Fortuin FD, Kereiakes DJ, Mendelsohn FO, Sherman W, Schaer GL, White CJ, Stewart D, Story K, Losordo DW, Henry TD.

Am Heart J. 2013 Jun;165(6):854-861.e2. doi: 10.1016/j.ahj.2013.03.003. Epub 2013 Apr 19.


Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial.

Losordo DW, Schatz RA, White CJ, Udelson JE, Veereshwarayya V, Durgin M, Poh KK, Weinstein R, Kearney M, Chaudhry M, Burg A, Eaton L, Heyd L, Thorne T, Shturman L, Hoffmeister P, Story K, Zak V, Dowling D, Traverse JH, Olson RE, Flanagan J, Sodano D, Murayama T, Kawamoto A, Kusano KF, Wollins J, Welt F, Shah P, Soukas P, Asahara T, Henry TD.

Circulation. 2007 Jun 26;115(25):3165-72. Epub 2007 Jun 11.


Relation of minor cardiac troponin I elevation to late cardiac events after uncomplicated elective successful percutaneous transluminal coronary angioplasty for angina pectoris.

Bertinchant JP, Polge A, Ledermann B, Genet L, Fabbro-Peray P, Raczka F, Brunet J, Poirey S, Wittenberg O, Pernel I, Nigond J.

Am J Cardiol. 1999 Jul 1;84(1):51-7.


Intramyocardial, autologous CD34+ cell therapy for refractory angina.

Losordo DW, Henry TD, Davidson C, Sup Lee J, Costa MA, Bass T, Mendelsohn F, Fortuin FD, Pepine CJ, Traverse JH, Amrani D, Ewenstein BM, Riedel N, Story K, Barker K, Povsic TJ, Harrington RA, Schatz RA; ACT34-CMI Investigators.

Circ Res. 2011 Aug 5;109(4):428-36. doi: 10.1161/CIRCRESAHA.111.245993. Epub 2011 Jul 7.


Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up.

Vrtovec B, Poglajen G, Lezaic L, Sever M, Domanovic D, Cernelc P, Socan A, Schrepfer S, Torre-Amione G, Haddad F, Wu JC.

Circ Res. 2013 Jan 4;112(1):165-73. doi: 10.1161/CIRCRESAHA.112.276519. Epub 2012 Oct 12.


Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G; 3101 Investigators.

J Clin Oncol. 2009 Oct 1;27(28):4767-73. doi: 10.1200/JCO.2008.20.7209. Epub 2009 Aug 31.


Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF.

Biol Blood Marrow Transplant. 2008 Sep;14(9):1045-56. doi: 10.1016/j.bbmt.2008.07.004.


A randomized, double-blind, placebo-controlled, multicenter, pilot study of the safety and feasibility of catheter-based intramyocardial injection of AdVEGF121 in patients with refractory advanced coronary artery disease.

Fuchs S, Dib N, Cohen BM, Okubagzi P, Diethrich EB, Campbell A, Macko J, Kessler PD, Rasmussen HS, Epstein SE, Kornowski R.

Catheter Cardiovasc Interv. 2006 Sep;68(3):372-8.


Intracoronary autologous CD34+ stem cell therapy for intractable angina.

Wang S, Cui J, Peng W, Lu M.

Cardiology. 2010;117(2):140-7. doi: 10.1159/000320217. Epub 2010 Oct 23.


Safety and efficacy of peripheral blood progenitor cell mobilization and collection in patients with advanced coronary heart disease.

Sinha S, Poh KK, Sodano D, Flanagan J, Ouilette C, Kearney M, Heyd L, Wollins J, Losordo D, Weinstein R.

J Clin Apher. 2006 Jul;21(2):116-20.


Long-term benefit of intracardiac delivery of autologous granulocyte-colony-stimulating factor-mobilized blood CD34+ cells containing cardiac progenitors on regional heart structure and function after myocardial infarct.

Pasquet S, Sovalat H, Hénon P, Bischoff N, Arkam Y, Ojeda-Uribe M, Bouar Rl, Rimelen V, Brink I, Dallemand R, Monassier JP.

Cytotherapy. 2009;11(8):1002-15. doi: 10.3109/14653240903164963.


Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens.

Stewart DA, Guo D, Morris D, Poon MC, Ruether BA, Jones AR, Klassen J, Auer I, Luider J, Chaudhry A, Brown C, Russell JA.

Bone Marrow Transplant. 1999 Jan;23(2):111-7.


Prediction of outcome after percutaneous coronary intervention for the acute coronary syndrome.

Kini AS, Lee PC, Mitre CA, Kim MC, Kamran M, Duffy ME, Marmur JD, Sharma SK.

Am J Med. 2003 Dec 15;115(9):708-14.


Supplemental Content

Support Center